Novellia CEO Shashi Shankar Named to Worth Magazine's 2025 AI & Health Access Pioneer List

Award recognizes leaders using AI to expand equity and reshape access to care

NEW YORK, June 12, 2025 /PRNewswire/ -- Novellia, Inc., the AI health data platform trusted by leading biopharma companies to uncover hidden insights in real-world patient data, today announced that its CEO and co-founder Shashi Shankar has been named to Worth Magazine's 2025 AI & Health Access Pioneer list. The award honors 10 changemakers using artificial intelligence to expand access to high-quality care and address structural barriers in healthcare delivery.

Shankar was recognized for his leadership in building Novellia's AI-enabled health data platform, which transforms messy, fragmented patient records into clean, longitudinal stories that are structured from the start and ready for action. For patients, this means greater clarity, control, and the ability to advocate for their own care. For biopharma teams, it means faster access to the right signals—like early risk indicators or gaps in treatment—so they can improve uptake, reduce delays, and develop therapies that truly work in the real world.

"We started Novellia so that scattered medical records would never again stand in the way of delivering the care someone deserves, like they did for my grandfather," said Shashi Shankar, CEO and co-founder of Novellia. "Today, our AI platform is helping people across the U.S. become their own best advocate, while giving researchers and biopharma teams a clearer view of the full patient story, so they can spot risks sooner, improve treatment uptake, and develop therapies that truly work for everyone. This recognition from Worth is incredibly meaningful because it affirms that AI's most powerful role in healthcare isn't to build more efficiencies—it's to drive better outcomes."

Shankar's recognition comes amid a wave of momentum for Novellia:

• Last month, the company announced the launch of Project EVEREST, a landmark cross-industry research initiative designed to improve treatment adherence and care equity in breast cancer. Supported by Daiichi Sankyo, Genentech, and AstraZeneca, the project unites leading institutions and uses Novellia's platform to surface gaps in real-world care delivery. 
  
  
• Novellia was named the "Best Electronic Health Record Service" in the 2025 MedTech Breakthrough Awards, recognized for AI innovation in patient-controlled health record platforms. 

About Novellia
Novellia is the AI-enabled data partner trusted by leading biopharma companies to uncover hidden insights in real-world patient data. Through proprietary AI and patient-permissioned data access, Novellia unifies fragmented records into full, sequential patient stories to surface critical trends and signals that traditional data providers miss.

Novellia's patient-facing platform empowers individuals to become their own best advocate in their care journey by centralizing health records, enabling personalized, proactive care management, and offering the choice to contribute anonymized data to support medical research. This depth of insight helps biopharma close the gap between data and decisions to advance therapeutic development and enable more effective, patient-centered care.

Novellia was recently named "Best Electronic Health Record Service" in the 9th annual MedTech Breakthrough Awards program, recognizing its leadership and innovation in AI-powered health data. To learn more visit novellia.com.

Media Contact
Novellia Communications
[email protected]

SOURCE Novellia